Head to Head Review: Oruka Therapeutics (ORKA) and Its Rivals

Oruka Therapeutics (NASDAQ:ORKA) is one of 37 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka Therapeutics to related companies based on the strength of its analyst recommendations, valuation, profitability, earnings, institutional ownership, dividends and risk.

Profitability

This table compares Oruka Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Oruka Therapeutics Competitors	-2,020.97%	-42.23%	-27.11%

Valuation & Earnings

This table compares Oruka Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oruka Therapeutics	N/A	-$5.34 million	-4.63
Oruka Therapeutics Competitors	$575.35 million	$6.55 million	-34.29

Oruka Therapeutics’ peers have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings for Oruka Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	6	2	3.25
Oruka Therapeutics Competitors	850	798	1343	23	2.18

Oruka Therapeutics presently has a consensus target price of $43.17, suggesting a potential upside of 55.16%. As a group, “Diagnostic substances” companies have a potential upside of 31.94%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Oruka Therapeutics is more favorable than its peers.

Volatility and Risk

Oruka Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ peers have a beta of 1.33, suggesting that their average share price is 33% more volatile than the S&P 500.

Institutional & Insider Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 45.9% of shares of all “Diagnostic substances” companies are owned by institutional investors. 30.9% of Oruka Therapeutics shares are owned by insiders. Comparatively, 13.4% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Oruka Therapeutics beats its peers on 10 of the 13 factors compared.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.